About investor relations

Henry Schein at a Glance

About investor relations


Our Q3 Results Reflect

  • Management is highly focused on increasing productivity and margins across each of our businesses, delivering 55bps non-GAAP operating margin expansion.
  • Overall, we are executing to plan, narrowing our 2022 diluted EPS guidance range which reflects our underlying confidence in the strength and stability of our business.
  • Solid underlying sales growth of 6.8% (excluding PPE and COVID-19 Test Kits) across our business and in most geographies, driven by excellent growth in our Medical and Technology businesses and in Dental equipment.

At Henry Schein, Inc., our customers rely on us for an exceptional experience

Delivering differentiated solutions that make their practices more successful and improve patient outcomes. We are trusted advisors and consultants to our customers – enabling them to deliver the best quality patient care and enhance their practice management efficiency and profitability.

With more than 3,400 field sales consultants (including equipment sales specialists), approximately 2,100 telesales representatives, and more than 170 equipment sales and service centers worldwide, Henry Schein helps customers succeed by offering the products and services needed for delivering high-quality health care.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.